Proxy Biomedical and REMEDI have started an exciting collaboration to develop new treatments for osteoarthritis using novel tissue engineering approaches.
REMEDI and Creganna-Tactx Medical are working on developing next generation solutions for delivery of stem cell therapies.
Orbsen Therapeutics Limited aims to become a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions.
REMEDI's major industrial healthcare cooperation is with Medtronic Inc., a world leader in medical device technologies. REMEDI and Medtronic have partnered since 2004 to identify and develop new treatments for vascular diseases.
Ovagen are working with REMEDI in a number of areas including using their germ free chicken technology to develop recombinant proteins for regenerative medicine applications.
REMEDI and Ziel Biopharma are co-developing methods for enhancing stem cell efficacy using a unique encapsulation method.
REMEDI in partnership with Smith & Nephew is developing new therapies using adult bone marrow stem cells to promote the re-growth of healthy cartilage and repair damaged joints.
REMEDI has commenced a collaboration with EnBIO developing medical devices and implants with enhanced properties.
World-leading experts from the field of stem cell science will convene at NUI Galway on 29-30 October 2014.